TPS218 Background: The ABC-02 trial (Valle ASCO 2009, abstr. 4503), the largest ever randomized phase III trial in ABC to date, demonstrated a significant survival advantage for GemCis over Gem alone (11.7 vs. 8.2 months [log rank p=0.002], with hazard ratio 0.68 [95%-CI 0.53, 0.86]) without added clinically significant toxicity. ABCs are associated with an increase in VEGF expression, which in turn correlates with the presence of metastatic disease. Cediranib is a highly potent inhibitor of VEGFR2 tyrosine kinase and VEGF-induced signaling in endothelial cells. Cediranib is expected, at chronic oral dosing, to inhibit VEGF driven angiogenesis and, as a consequence, constrain tumor growth. ABC-03 compares GemCis with either cediranib or with placebo. This randomized phase II trial, will recruit 136 pts, with progression-free survival (PFS) as the primary endpoint. Methods: Consenting pts with histologically/cytologically confirmed ABC, aged ≥18 years, ECOG performance status 0-2 and adequate haematologica...